Details of the Drug Combination

General Information of Drug Combination (ID: DC8OILK)

Drug Combination Name
Brigatinib Lorlatinib
Indication
Disease Entry Status REF
Lung Non-Squamous Non-Small Cell Carcinoma Phase 2 [1]
Component Drugs Brigatinib   DM7W94S Lorlatinib   DMICDLV
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Brigatinib
Disease Entry ICD 11 Status REF
Anaplastic large cell lymphoma 2A90.A Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [3]
Brigatinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Brigatinib Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]
ATP-binding cassette sub-family B member 5 (ABCB5) DTKVEXO ABCB5_HUMAN Substrate [5]
------------------------------------------------------------------------------------
Brigatinib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Lorlatinib
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [4]
Lorlatinib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Inhibitor [4]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Lorlatinib Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [7]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [7]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [7]
UDP-glucuronosyltransferase 1A4 (UGT1A4) DELOY3P UD14_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)

References

1 ClinicalTrials.gov (NCT03737994) Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
6 Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135.
7 FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
8 Product characteristics of Lorviqua.